Welcome to our dedicated page for DAXOR SEC filings (Ticker: DXR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Daxor Corporation (NASDAQ: DXR) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures as a public issuer. Daxor is a medical instrumentation and biotechnology company focused on blood volume measurement, and its filings offer detail on corporate events, governance and the development of its Blood Volume Analysis (BVA) technology.
Through current reports such as Form 8-K, Daxor discloses material events, including FDA 510(k) clearance for its next-generation rapid, portable, lab-based Blood Volume Analyzer (Daxor BVA™) and outcomes of shareholder meetings, such as director elections and auditor ratification. These documents also restate the company’s description as a developer and marketer of the BVA-100 Blood Volume Analyzer, the first FDA-cleared diagnostic blood test to objectively quantify blood volume status and composition compared to patient-specific norms.
On Stock Titan, users can review Daxor’s SEC filings alongside AI-powered summaries that explain the significance of each document in clear language. This includes annual and quarterly reports when filed (Forms 10-K and 10-Q), which typically discuss the company’s business, risk factors and financial condition, as well as Form 4 and related insider transaction reports when available, which detail trades by directors and officers.
Real-time updates from the SEC’s EDGAR system help ensure that new DXR filings are quickly reflected. The AI tools on the platform can highlight key points in lengthy filings, such as descriptions of the BVA product line, regulatory milestones, and information about the company’s Nasdaq listing and corporate structure. This makes it easier for investors and researchers to understand how Daxor’s regulatory disclosures relate to its blood volume analysis business.
Daxor Corp reported an insider equity transaction by its Chief Financial Officer, Robert J. Michel. On December 9, 2025, he acquired 3,000 shares of Daxor common stock at a stated price of $0, reflecting the vesting of a stock grant.
Following this transaction, the CFO beneficially owns 20,050 shares of Daxor common stock in direct ownership, according to the Form 4 disclosure.
Daxor Corp (DXR) reported an insider equity event by its Chief Medical Officer, John Jefferies. On November 12, 2025, he acquired 2,344 shares of Daxor common stock at a reported price of $0, coded as “P,” with the filing noting these shares were from a grant that vested on November 12, 2025.
Following this transaction, Jefferies beneficially owns 17,616 shares with direct ownership. The filing was made by one reporting person and identifies his role as Officer (Chief Medical Officer).
John Jefferies, Chief Medical Officer of DAXOR CORP (DXR), filed an Initial Statement of Beneficial Ownership reporting 15,272 shares of DAXOR common stock owned directly. The filing lists multiple stock options exercisable for a total of ≈18,181 underlying shares across various grant dates and strike prices, with several tranches vesting by 12/01/2025 and one option presently exercisable in full.
Daxor (DXR) filed a routine Form 4 disclosing that director Henry D. Cremisi received an option grant for 2,500 common-stock shares on June 24 2025 under the company’s 2020 Incentive Compensation Plan, contingent upon SEC approval of an amendment to that plan. The options carry a $9.29 exercise price and vest in three annual tranches (833/883/834 shares through 2027). No DXR shares were bought or sold, and Cremisi’s beneficial ownership now includes the new grant. The filing does not report any other transactions or material changes.
Daxor – DXR filed a Form 4 reporting that director Edward Feuer was granted 2,500 stock options on 24 June 2025 at an exercise price of $9.29. The award is contingent on SEC approval of an amendment to the company’s 2020 Incentive Compensation Plan.
The options vest in three tranches—833 on 24 Jun 2025, 883 on 24 Jun 2026 and 834 on 24 Jun 2027—and expire on 24 Jun 2030. No common shares were bought or sold, and beneficial ownership remains solely derivative. The filing represents routine equity compensation rather than an open-market transaction.
Daxor (NASDAQ:DXR) filed a Form 4 reporting the grant of 2,500 non-qualified stock options to director Joy S. Goudie on June 24 2025 at an exercise price of $9.29 per share, expiring June 24 2030.
The award is contingent upon SEC approval of an amendment to the company’s 2020 Incentive Compensation Plan and vests in three tranches: 833 options on June 24 2025, 883 on June 24 2026, and 834 on June 24 2027. No open-market purchases or sales were disclosed; the filing solely records the new derivative position. Following the transaction, Goudie beneficially owns 2,500 options with no change to her reported direct share ownership.
Daxor Corporation (DXR) filed a Form 4 on 26-Jun-2025 disclosing that director Caleb DesRosiers received 2,500 non-qualified stock options on 24-Jun-2025. The options carry an exercise price of $9.29 and expire on 24-Jun-2030. Vesting occurs in three installments: 833 options on 24-Jun-2025, 833 on 24-Jun-2026 and 834 on 24-Jun-2027. Following the grant, DesRosiers beneficially owns 2,500 derivative securities directly.
The award is contingent on SEC approval of an amendment to the Daxor Corporation 2020 Incentive Compensation Plan. No common-stock purchases or sales were reported, making this a routine compensation-related disclosure rather than a signal of insider sentiment.
FAQ
What is the current stock price of DAXOR (DXR)?
What is the market cap of DAXOR (DXR)?
